Ocular Therapeutix (OCUL) Revenue (2014 - 2026)
Ocular Therapeutix's quarterly Revenue came in at $10.8 million in Q1 2026, up 0.81% year-on-year from $10.7 million in Q1 2025, and down 18.6% quarter-over-quarter from $13.2 million in Q4 2025.
Ocular Therapeutix has reported Revenue for 13 years, with the latest figure at $10.8 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue rose 0.81% year-over-year to $10.8 million; the trailing twelve-month figure through Mar 2026 stood at $52.0 million (down 12.76% YoY), and the FY2025 full-year result was $52.0 million, down 18.47% from the prior year.
- Revenue for Q1 2026 stood at $10.8 million, down from $13.2 million in the prior quarter.
- The five-year high for Revenue was $17.1 million in Q4 2024, with the low at $10.7 million in Q1 2025.
- Average Revenue over 5 years is $13.9 million, with a median of $14.1 million recorded in 2022.
- Year-over-year, Revenue jumped 79.61% in 2022 and retreated 27.59% in 2025.
- Tracing OCUL's Revenue over 5 years: stood at $14.1 million in 2022, then increased by 5.16% to $14.8 million in 2023, then increased by 15.41% to $17.1 million in 2024, then declined by 22.43% to $13.2 million in 2025, then dropped by 18.6% to $10.8 million in 2026.
- The last three Revenue figures came in at $10.8 million (Q1 2026), $13.2 million (Q4 2025), and $14.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 10.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.79 Mn |
| Dec 31, 2025 | 13.25 Mn |
| Sep 30, 2025 | 14.54 Mn |
| Jun 30, 2025 | 13.46 Mn |
| Mar 31, 2025 | 10.70 Mn |
| Dec 31, 2024 | 17.08 Mn |
| Sep 30, 2024 | 15.43 Mn |
| Jun 30, 2024 | 16.44 Mn |
| Mar 31, 2024 | 14.77 Mn |
| Dec 31, 2023 | 14.80 Mn |
| Sep 30, 2023 | 15.08 Mn |
| Jun 30, 2023 | 15.19 Mn |
| Mar 31, 2023 | 13.37 Mn |
| Dec 31, 2022 | 14.08 Mn |
| Sep 30, 2022 | 11.97 Mn |
| Jun 30, 2022 | 12.27 Mn |
| Mar 31, 2022 | 13.19 Mn |
| Dec 31, 2021 | 12.31 Mn |
| Sep 30, 2021 | 12.15 Mn |
| Jun 30, 2021 | 11.72 Mn |
| Mar 31, 2021 | 7.34 Mn |
| Dec 31, 2020 | 7.35 Mn |
| Sep 30, 2020 | 5.88 Mn |
| Jun 30, 2020 | 1.57 Mn |
| Mar 31, 2020 | 2.61 Mn |
| Dec 31, 2019 | 2.26 Mn |
| Sep 30, 2019 | 829,000.00 |
| Jun 30, 2019 | 650,000.00 |
| Mar 31, 2019 | 492,000.00 |
| Dec 31, 2018 | 504,000.00 |
| Sep 30, 2018 | 498,000.00 |
| Jun 30, 2018 | 648,000.00 |
| Mar 31, 2018 | 340,000.00 |
| Dec 31, 2017 | 487,000.00 |
| Sep 30, 2017 | 523,000.00 |
| Jun 30, 2017 | 438,000.00 |
| Mar 31, 2017 | 475,000.00 |
| Dec 31, 2016 | 511,000.00 |
| Sep 30, 2016 | 477,000.00 |
| Jun 30, 2016 | 441,000.00 |
| Mar 31, 2016 | 416,000.00 |
| Dec 31, 2015 | 394,000.00 |
| Sep 30, 2015 | 41,000.00 |
| Jun 30, 2015 | 459,000.00 |
| Mar 31, 2015 | 238,000.00 |
| Dec 31, 2014 | 505,000.00 |
| Sep 30, 2014 | 143,000.00 |
| Jun 30, 2014 | 97,000.00 |
| Mar 31, 2014 | 27,000.00 |